Your browser doesn't support javascript.
loading
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu, Heikki; Eriksson, Mikael; Sundby Hall, Kirsten; Hartmann, Jörg T; Pink, Daniel; Schütte, Jochen; Ramadori, Giuliano; Hohenberger, Peter; Duyster, Justus; Al-Batran, Salah-Eddin; Schlemmer, Marcus; Bauer, Sebastian; Wardelmann, Eva; Sarlomo-Rikala, Maarit; Nilsson, Bengt; Sihto, Harri; Monge, Odd R; Bono, Petri; Kallio, Raija; Vehtari, Aki; Leinonen, Mika; Alvegård, Thor; Reichardt, Peter.
Affiliation
  • Joensuu H; Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 180, FIN-00029 Helsinki, Finland. heikki.joensuu@hus.fi
JAMA ; 307(12): 1265-72, 2012 Mar 28.
Article in En | MEDLINE | ID: mdl-22453568
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Piperazines / Pyrimidines / Gastrointestinal Stromal Tumors / Gastrointestinal Neoplasms / Antineoplastic Agents Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2012 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Piperazines / Pyrimidines / Gastrointestinal Stromal Tumors / Gastrointestinal Neoplasms / Antineoplastic Agents Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2012 Type: Article